C'elle(SM) Featured on ABC Action News in Tampa Bay
20 Julio 2009 - 7:00AM
PR Newswire (US)
Advances in Menstrual Stem Cell Technology May End Stem Cell
Controversy Oldsmar, Fla., July 20 /PRNewswire-FirstCall/ -- Women
today have a number of options when it comes to protecting their
future health and possibly that of their families. Banking stem
cells found in menstrual blood is one way in which women are
looking to safeguard against potential future illnesses, conditions
or injuries. Menstrual blood has been shown to contain
self-renewing stem cells that may be stored for potential
treatments in the future. A Florida-based company, Cryo-Cell
International, Inc. (OTC Bulletin Board: CCEL) offers C'elle, a
service that empowers women to collect and preserve stem cells
harvested from their own menstrual blood. Featured in a recent
healthcare segment on ABC Action News in Tampa Bay, the promise of
C'elle technology offers insightful perspectives from a C'elle
client and from a stem cell researcher who is exploring development
of Cryo-Cell's proprietary cutting edge technology for a potential
neurological application. Cryo-Cell discovered that menstrual flow
contains millions of unique adult stem cells that demonstrate
properties similar to bone marrow and embryonic stem cells. These
stem cells have the potential to differentiate into possibly every
other cell type in the human body. This finding represents an
important step forward in adult stem cell discoveries, as it is the
first time researchers have found an adult stem cell with these
properties. Menstrual stem cells (MenSCs) potentially offer
compelling advantages over stem cells obtained from other sources
because they can be easily obtained from women in a painless,
non-invasive manner, and they are an exact match for the woman
donor and therefore the patient's rejection of tissue may be
avoided. Since menstrual stem cells are harvested from a source
that would otherwise be regarded as biological waste, there are no
ethical questions that are associated with embryonic stem cells.
Cryo-Cell has established numerous pre-clinical (non-human)
research collaborations based on the expansive potential of C'elle
menstrual stem cell technology to study a broad range of possible
therapies to treat disorders including stroke, diabetes and
vascular regeneration, among others. In 2008, the Company announced
its collaboration with the National Institutes of Health (NIH),
whose scientists are conducting an exploratory study of MenSCs for
potential utilization in the treatment of breast cancer. This
collective body of ongoing research may potentially change the
types of therapies used to diagnose or treat a host of significant
medical conditions in the future. "We are clearly excited as
Cryo-Cell continues to build a significant pipeline of strong
research partnerships that are independently funded and that may
possibly lead to breakthrough therapies for future human clinical
studies," said Mercedes A. Walton, Chairman and CEO of Cryo-Cell.
"We are also pleased to empower women with the opportunity to
harvest and cryopreserve their own stem cells today for possible
utilization in the future." Cryo-Cell is one of the largest and
most established family cord blood banks with nearly 185,000
clients worldwide. The first cord blood stem cell transplant
occurred in 1988 and some twenty-one years later in 2009, over
12,000 cord blood stem cell transplants have taken place worldwide.
To view the ABC News feature on C'elle visit:
http://www.abcactionnews.com/content/taking_action_for_you/story/Is-the-stem-c
ell-controversy-coming-to-an-end/wbAmXpZW8EqVyrMkMiR8Hg.cspx About
C'elle The C'elle(SM) service was introduced in November 2007 as
the first and only service that empowers women to collect and
cryopreserve menstrual flow containing undifferentiated adult stem
cells for future utilization by the donor or possibly their
first-degree relatives in a manner similar to umbilical cord blood
stem cells. For more information, visit http://www.celle.com/ About
Cryo-Cell International, Inc. (OTCBB: CCEL.OB) Based in Oldsmar,
Florida, with nearly 185,000 clients worldwide, Cryo-Cell is one of
the largest and most established family cord blood banks. ISO
9001:2000 certified and accredited by the AABB, Cryo-Cell operates
in a state-of-the-art Good Manufacturing Practice and Good Tissue
Practice (cGMP/cGTP)-compliant facility. Cryo-Cell is a publicly
traded company. OTC Bulletin Board Symbol: CCEL. For more
information, please call 1-800-STOR-CELL (1-800-786-7235) or visit
http://www.cryo-cell.com/. Forward-Looking Statement Statements
wherein the terms "believes", "intends", "projects" or "expects" as
used are intended to reflect "forward-looking statements" of the
Company. The information contained herein is subject to various
risks, uncertainties and other factors that could cause actual
results to differ materially from the results anticipated in such
forward-looking statements or paragraphs, many of which are outside
the control of the Company. These uncertainties and other factors
include the uncertainty of market acceptance of any potential
service offerings relating to types of stem cells other than cord
blood stem cells, including the C'elle service, given that
menstrual stem cells and other new stem cells have not yet been
used in human therapies, and treatment applications using such stem
cells are not likely to be developed and commercialized for many
years and are subject to further research and development; the need
for additional development and testing before determining the
ultimate commercial value of the Company's intellectual property
relating to the menstrual stem cells; the need to complete certain
developments, including completion of clinical validation and
testing, before any new process other than C'elle can be
commercialized, and the Company's development of its final business
and economic model in offering any such service; any adverse effect
or limitations caused by recent increases in government regulation
of stem cell storage facilities; any increased competition in our
business; any decrease or slowdown in the number of people seeking
to store umbilical cord blood stem cells or decrease in the number
of people paying annual storage fees; any adverse impacts on our
revenue or operating margins due to the costs associated with
increased growth in our business, including the possibility of
unanticipated costs relating to the operation of our new facility;
any technological breakthrough or medical breakthrough that would
render the Company's business of stem cell preservation obsolete;
any material failure or malfunction in our storage facilities; any
natural disaster such as a tornado, other disaster (fire) or act of
terrorism that adversely affects stored specimens; the costs
associated with defending or prosecuting litigation matters and any
material adverse result from such matters; decreases in asset
valuations; any continued negative effect from adverse publicity in
the past year regarding the Company's business operations; any
negative consequences resulting from deriving, shipping and storing
specimens at a second location; and other risks and uncertainties.
The foregoing list is not exhaustive, and the Company disclaims any
obligations to subsequently revise any forward-looking statements
to reflect events or circumstances after the date of such
statements. Readers should carefully review the risk factors
described in other documents the Company files from time to time
with the Securities and Exchange Commission, including the most
recent Annual Report on Form 10-KSB, Quarterly Reports on Form
10-QSB and any Current Reports on Form 8-K filed by the Company.
Contact: General Media Inquiries Kristin O'Neill 312-233-1295
Financial Media Inquiries: Cryo-Cell International, Inc. Investor
Relations Dianne Will 518-398-6222 DATASOURCE: Cryo-Cell
International, Inc. CONTACT: General Media Inquiries, Kristin
O'Neill, +1-312-233-1295, ; or Financial Media Inquiries, Dianne
Will, Investor Relations, Cryo-Cell International, Inc.,
+1-518-398-6222, Web Site: http://www.cryo-cell.com/
Copyright